NEUROMICS
Integrated European –omics research project for diagnosis and therapy in rare neuromuscular and neurodegenerative diseases
| Coordinatore | EBERHARD KARLS UNIVERSITAET TUEBINGEN
Organization address
address: GESCHWISTER-SCHOLL-PLATZ contact info |
| Nazionalità Coordinatore | Germany [DE] |
| Totale costo | 16˙846˙062 € |
| EC contributo | 12˙000˙000 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2012-INNOVATION-1 |
| Funding Scheme | CP-IP |
| Anno di inizio | 2012 |
| Periodo (anno-mese-giorno) | 2012-10-01 - 2017-09-30 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
EBERHARD KARLS UNIVERSITAET TUEBINGEN
Organization address
address: GESCHWISTER-SCHOLL-PLATZ contact info |
DE (TUEBINGEN) | coordinator | 1˙548˙720.60 |
| 2 |
ISLENSK ERFDAGREINING EHF
Organization address
address: Sturlugata 8 contact info |
IS (REYKJAVIK) | participant | 2˙191˙500.00 |
| 3 |
UNIVERSITY OF NEWCASTLE UPON TYNE
Organization address
address: Kensington Terrace 6 contact info |
UK (NEWCASTLE UPON TYNE) | participant | 1˙020˙478.00 |
| 4 |
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
Organization address
address: 101 Rue de Tolbiac contact info |
FR (PARIS) | participant | 993˙999.60 |
| 5 |
UNIVERSITY COLLEGE LONDON
Organization address
address: GOWER STREET contact info |
UK (LONDON) | participant | 952˙601.00 |
| 6 |
KLINIKUM DER UNIVERSITAET ZU KOELN
Organization address
address: Kerpener Strasse 62 contact info |
DE (KOELN) | participant | 796˙300.00 |
| 7 |
ACADEMISCH ZIEKENHUIS LEIDEN
Organization address
address: Albinusdreef 2 contact info |
NL (LEIDEN) | participant | 747˙400.00 |
| 8 |
VIB
Organization address
address: Rijvisschestraat 120 contact info |
BE (ZWIJNAARDE - GENT) | participant | 613˙200.00 |
| 9 |
UNIVERSITE D'AIX MARSEILLE
Organization address
address: Boulevard Charles Livon 58 contact info |
FR (Marseille) | participant | 528˙000.00 |
| 10 |
PROFILOMIC SA
Organization address
address: RUE D AGUESSEAU 31 contact info |
FR (BOULOGNE BILLANCOURT) | participant | 492˙400.00 |
| 11 |
ARIADNE DIAGNOSTICS LLC
Organization address
address: KEY WEST AVE 9430 SUITE 115 contact info |
US (ROCKVILLE) | participant | 480˙000.00 |
| 12 |
DEUTSCHES ZENTRUM FUER NEURODEGENERATIVE ERKRANKUNGEN EV
Organization address
address: LUDWIG-ERHARD-ALLEE 2 contact info |
DE (BONN) | participant | 367˙000.80 |
| 13 |
BIO-PRODICT BV
Organization address
address: DREIJENPLEIN 10 contact info |
NL (WAGENINGEN) | participant | 252˙000.00 |
| 14 |
THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE
Organization address
address: The Old Schools, Trinity Lane contact info |
UK (CAMBRIDGE) | participant | 246˙000.00 |
| 15 |
UNIVERSITA DEGLI STUDI DI MILANO
Organization address
address: Via Festa Del Perdono 7 contact info |
IT (MILANO) | participant | 246˙000.00 |
| 16 |
UNIVERSITA DEGLI STUDI DI FERRARA
Organization address
address: SAVONAROLA 9 contact info |
IT (FERRARA) | participant | 244˙000.00 |
| 17 |
AGILENT TECHNOLOGIES SWEDEN AB
Organization address
address: KRONBORGSGRAND 23 contact info |
SE (KISTA) | participant | 200˙400.00 |
| 18 |
UNIVERSITAETSKLINIKUM FREIBURG
Organization address
address: HUGSTETTER STRASSE 49 contact info |
DE (FREIBURG) | participant | 80˙000.00 |
| 19 |
THE UNIVERSITY OF WESTERN AUSTRALIA
Organization address
address: Stirling Higway 35 contact info |
AU (CRAWLEY) | participant | 0.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'Neurodegenerative (ND) and neuromuscular (NM) disease is one of the most frequent classes of rare diseases, affecting life and mobility of 500,000 patients in Europe and millions of their caregivers, family members and employers. This NEUROMICS project brings together the leading research groups in Europe, five highly innovative SMEs and relevant oversea experts using the most sophisticated Omics technologies to revolutionize diagnostics and to develop pathomechanism-based treatment for ten major ND and NM diseases. Specifically we aim to: (i) use next generation WES to increase the number of known gene loci for the most heterogeneous disease groups from about 50% to 80%, (ii) increase patient cohorts by large scale genotyping by enriched gene variant panels and NGS of so far unclassified patients and subsequent phenotyping, (iii) develop biomarkers for clinical application with a strong emphasis on presymptomatic utility and cohort stratification, (iv) combine -omics approaches to better understand pathophysiology and identify therapeutic targets, (v) identify disease modifiers in disease subgroups cohorts with extreme age of onset (vi) develop targeted therapies (to groups or personalized) using antisense oligos and histone deacetylase inhibitors, translating the consortiums expertise in clinical development from ongoing trials toward other disease groups, notably the PolyQ diseases and other NMD. To warrant that advances affect a large fraction of patients we limited the selection to a number of major categories, some of which are in a promising stage of etiological and therapeutic research while some others are in great need of further classification. The efforts will be connected through a NEUROMICS platform for impact, communication and innovation that will provide tools and procedures for ensuring trial-readiness, WP performance, sustainability, interaction with the chosen Support IRDiRC and RD-Connect project and involvement of stakeholders in the NDD/NMD field.'